KPTI Stock Analysis: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$5.28
-0.20 (-3.65%)
▼
5d:
-20.72%
30d:
-43.89%
90d:
-29.03%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
KPTI is down 28.2% this week, but smart money is accumulating calls. Top strike: $7.5 2026-05-15 with 830 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KPTI is down 20.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KPTI is down 20.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $5.28, which is considered oversold relative to its 30-day fair value range of $7.14 to $9.80.
Technical Outlook: Technically, KPTI is in a uptrend. Immediate support is located at $5.00, while resistance sits at $9.04. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.83 (+134.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KPTI is in a uptrend. Immediate support is located at $5.00, while resistance sits at $9.04. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.83 (+134.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$7.14 -
$9.80
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 134.2% below Wall St target ($12.83)
- WARNING: Recommendation downgraded due to -20.7% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$7.14 -
$9.80
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.00
Resistance Level
$9.04
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.18
Wall Street Target
$12.83
(+134.2%)
Revenue Growth (YoY)
11.6%
Profit Margin
-134.2%
Share & Embed Analysis
Last updated: March 30, 2026 2:46 PM ET
Data refreshes hourly during market hours. Next update: 3:46 PM
Data refreshes hourly during market hours. Next update: 3:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Kristin Abate
SELL
50 shares
2026-01-28
Kristin Abate
SELL
265 shares
2026-01-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 63 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 57 HOLD |
